Our research partnerships with the NHS, industry, medical organisations and charities in the UK and across the world.
We have a long standing partnership with the NHS in the Thames Valley Region. Oxford is a leading medical centre in the UK serving some three million people in the immediate geographic area and, with its specialist units, receives referrals from across the UK and overseas. Many of these units have been set up and run with University support. University clinical academics have regular clinics at the five main NHS hospitals in Oxford - the John Radcliffe, the Radcliffe Infirmary, the Warneford, the Churchill and the Nuffield Orthopaedic Centre. We also work closely with the management of the local NHS Trusts - the Oxford Radcliffe Hospitals Trust, the Oxford Mental Healthcare Trust and Primary Care Trusts - to ensure that, together, we are not only meeting the needs of patients today but also looking forward to see how we can significantly improve patient care in the years to come.
Links with Industry & Medical Organisations
Oxford Medicine also has well established research partnerships with industry, medical organisations and charities in the UK and across the world. As a consequence, not only has our research funding grown substantially over the past decade but these partnerships have also played a critical role in helping us to realise our plans for essential new facilities. These include the Oxford Centre for Diabetes, Endocrinology and Metabolism (opened 2003), the Henry Wellcome Building of Gene Function (opened 2004) and the Richard Doll Building (opened 2005) which houses our clinical trials and epidemiology units.
Our work has also led to a burgeoning Oxford-based biotechnology industry, the genesis of which is in scientific innovation at the University. These new companies have benefited the local economy and created many new jobs in the region. Companies recently spun out from research in Oxford Medicine include Riotech Pharmaceuticals (hepatitis drugs), ReOx (new drugs based on hypoxic response) and Oxford Immunotec Ltd (TB tests).
We are delighted to announce that in recognition of the alliance between Oxford University and University College London, the Centre for the Acceleration of Medical Innovation (CAMI) is being renamed CASMI, the Centre for the Advancement of Sustainable Medical Innovation. CASMI’s board will now be chaired jointly by Sir John Bell of Oxford and Sir John Tooke of UCL. This unique venture not only offers the Centre the support, infrastructure and international reputation of both institutions but also maximises engagement with academics at the forefront of their fields.
CASMI aims to address the issues that have lead to current failures in the translation of basic bioscience into affordable and widely adopted new treatments.
CASMI will continue the work on Adaptive Licensing (a new approach to enabling earlier access for patients to new medicines), the regulation of cell therapy and the future environment for stratified medicine. In 2013 we plan to extend into other key areas central to the effective generation, development, regulation and adoption of innovative medical technologies, and we welcome dialogue with supporters and collaborators on this future agenda.